Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling
- Abderrahim Kadri1,
- Thomas Funck-Brentano1,
- Hilène Lin1,
- Hang-Korng Ea1,
- Didier Hannouche2,
- Caroline Marty1,
- Frédéric Lioté1,
- Valérie Geoffroy1,
- Martine E Cohen-Solal1
- 1INSERM U606, Centre Viggo Petersen and Université Paris-Diderot Paris 7, Hôpital Lariboisière, Paris, France
- 2UMR-CNRS 7052, Centre Viggo Petersen and Université Paris-Diderot Paris 7, Hôpital Lariboisière, Paris, France
- Correspondence to Dr Martine E Cohen-Solal, INSERM U606, Centre Viggo Petersen and Université Paris-Diderot Paris 7, Hôpital Lariboisière, 2 rue Ambroise Paré, Paris 75010, France;
- Accepted 26 January 2010
- Published Online First 4 June 2010
Background Osteoarthritis (OA) is characterised by cartilage degradation and bone lesions. Subchondral bone may be involved in the pathogenesis of cartilage matrix breakdown.
Objective To assess the role of bone remodelling in OA by studying the effect of bisphosphonate on OA development in mice with high bone remodelling.
Methods Mice overexpressing Runx2 (Runx2-Tg) under the control of collagen type I that displayed high bone remodelling were used. Joint instability was performed by partial medial meniscectomy to induce OA.
Results Six weeks after surgery, tibial cartilage of Runx2-Tg mice displayed an increased number of ADAMTS-4- and ADAMTS-5-expressing chondrocytes compared with controls (p<0.05). This increase was higher in Runx2-Tg mice than in wild-type mice, although their OA score did not differ (2.5±0.6 vs 2.4±0.2, P=NS). Pamidronate reduced the OA score in Runx2-Tg mice but not in wild-type littermates (1.2±0.5 vs 2.7±0.4; p<0.05) despite the reduction of bone resorption and of the expression of cartilage proteases in both genotypes.
Conclusions These findings support the hypothesis that the level of bone resorption influences cartilage metabolism and that inhibition might prevent the progression of OA. Targeting bone resorption might therefore provide an approach to the treatment of high bone resorbing forms of OA.
Competing interest None.
Provenance and peer review Not commissioned; externally peer reviewed.